Atlas Two · Pathogen · Parasite

Giardia lamblia

The most common intestinal protozoan worldwide — a diplomonad time capsule thriving without mitochondria, using a hydrodynamic suction disc to colonise your duodenum.

Giardia lamblia (also G. intestinalis / G. duodenalis) infects 280–300 million people per year. Pear-shaped trophozoites attach to duodenal and jejunal epithelium via the ventral adhesive disc, disrupting tight junctions, stripping microvilli, and triggering malabsorption — all without ever invading host tissue. VSP antigenic variation drives immune escape. Chronic infection stunts childhood growth; treatment is highly effective with single-dose tinidazole.

280–300MCases per year
~10Cysts to infect
~190VSP gene variants
8Flagella (4 pairs)
90–95%Tinidazole cure rate
Metamonada · Diplomonadida · Non-motile cyst + flagellate trophozoite · 9–21 µm

Giardia lamblia

Binucleate flagellated protozoan and one of the earliest-diverging eukaryotic lineages. Trophozoites colonise the duodenum and jejunum and attach exclusively via the ventral adhesive disc — a rigid cytoskeletal organelle generating hydrodynamic suction via flagellar beating. Infection is strictly extracellular: tight junctions are disrupted by cysteine protease cleavage of ZO-1 (via PAR-2/PKC/claudin-2), brush border disaccharidases are displaced, and bile salts are deconjugated — producing a combined osmotic and secretory diarrhoea with steatorrhoea. VSP antigenic switching (epigenetically regulated, ~190 variants) continuously subverts mucosal IgA. In hypogammaglobulinaemia (CVID), absence of IgA allows chronic, treatment-refractory infection. Single-dose tinidazole (2 g) achieves 90–95% cure.

Classification & Structure

Kingdom / SupergroupEukaryota; Excavata; Metamonada; Fornicata; Diplomonadida — one of the earliest-diverging eukaryotic lineages; sister group to Retortamonadida
Trophozoite9–21 µm × 5–15 µm, pear/tear-drop; 2 nuclei (symmetrically paired); 4 pairs of flagella (anterior, posterior-lateral, caudal, ventral); 1 ventral adhesive disc; 2 L-shaped median bodies (tubulin-based, function uncertain)
Cyst8–12 µm oval; 4 nuclei; β-1,3-GalNAc polymer wall (CWP1/2/3); extremely hardy — viable months in cold water; resistant to standard chlorination; killed by boiling or UV
Ventral adhesive discRigid concave cytoskeletal plate; spiral coil of α/β/γ-tubulin with contractile microribbons (giardins α, β, δ, ε, ζ — unique to Giardia); hydrodynamic low-pressure suction created by flagellar current; mannose-binding lectins supplement mechanical adhesion
VSP coat~190 Variant Surface Protein genes; only one expressed per trophozoite at a time; highly cysteine-rich; C-terminal CRGKA transmembrane anchor; forms dense protease-resistant coat; switched by IgA-driven epigenetic derepression (H3K4me3 / RNAi mechanism)
MitosomesRudimentary mitochondria-derived organelles retaining only Fe-S cluster assembly pathway; no oxidative phosphorylation; no conventional Golgi or peroxisomes — reflects deep evolutionary divergence and anaerobic lifestyle
Fermentation end-productsEthanol and acetate; cannot synthesise long-chain fatty acids de novo; relies on host bile for lipid acquisition

Infection Mechanism & Pathogenesis

1 · Transmission and excystation

Ingestion of as few as 10 cysts from contaminated water or food (the lowest infectious dose of any intestinal protozoan). Gastric acid (pH 2) triggers excystation; pancreatic trypsin in the duodenum completes the process — two trophozoites emerge per cyst within minutes. Cysts resist standard chlorination (require UV or filtration); person-to-person transmission in childcare centres and institutions; zoonotic transmission from beavers and dogs (assemblage A strains). VSPs are expressed immediately on emerging trophozoites.

2 · Ventral disc adhesion

Trophozoites colonise the duodenum and proximal jejunum — where bile (paradoxically) stimulates their growth. The ventral disc generates hydrodynamic suction via caudal flagellar current creating a low-pressure zone beneath the disc; α/β-giardin contractile microribbons adjust disc curvature to maximise contact with enterocyte microvilli. Mannose-binding lectins on the parasite surface provide additional adhesion to the enterocyte glycocalyx. Giardia is strictly extracellular and never invades the lamina propria.

3 · Tight junction disruption and barrier failure

Secreted cysteine proteases (CP2, CP14, CP49) cleave ZO-1 (zonula occludens-1) from tight junctions; trophozoite signalling via PAR-2 (protease-activated receptor 2) activates PKC, upregulating claudin-2 (paracellular cation channels). Claudin-1 and occludin are redistributed away from junctions. Simultaneously, disc adhesion physically strips microvilli from the brush border, reducing mucosal surface area. The result is a "leaky gut" phenotype with paracellular leak of luminal antigens and water.

4 · Malabsorption mechanisms

Brush border disaccharidases (lactase, sucrase, maltase) are displaced from the epithelial membrane → carbohydrate malabsorption → osmotic diarrhoea. Giardia deconjugates bile salts via its own hydrolases → deconjugated bile salts are ineffective emulsifiers → fat malabsorption → steatorrhoea. Cysteine protease activation of PAR-2 on enterocytes → increased Cl⁻ secretion via CFTR → secretory diarrhoea. The dual (osmotic + secretory) mechanism explains the classic foul-smelling, greasy, non-bloody stools of giardiasis.

5 · VSP antigenic variation and immune escape

One of ~190 VSP genes is expressed per trophozoite; silent VSPs are epigenetically suppressed (H3K4me3 marks the active locus; RNAi suppresses inactive loci). When mucosal IgA targeting the surface VSP accumulates, parasites switch expression to an alternative VSP — escaping antibody-mediated killing. This cycle allows chronic infection to persist despite IgA responses. In hypogammaglobulinaemia (CVID, agammaglobulinaemia), absence of secretory IgA leads to severe, treatment-refractory chronic giardiasis that requires repeated or long-term courses of antiparasitic therapy.

Host Immune Response

Mast cell degranulation (contributes to symptoms) PAR-2 activation by secreted cysteine proteases Partial TLR4 activation → limited NF-κB Mucosal secretory IgA against VSPs (drives antigenic switching) CD4+ Th1 response required for clearance Anti-VSP IgA in intestinal lumen → VSP switch pressure Hypogammaglobulinaemia (CVID) → chronic refractory infection DC maturation suppressed (IL-12 ↓) → impaired Th1

Disease Spectrum

PresentationProportionKey Features
Asymptomatic carriage~50–60%Cyst excretion without illness; common in endemic areas from partial acquired immunity; major reservoir for transmission
Acute giardiasis~40%1–3-week incubation; watery, foul-smelling, greasy, non-bloody diarrhoea; bloating, flatulence, abdominal cramps, nausea, weight loss; fever absent or low-grade; self-limited in 2–6 weeks in immunocompetent hosts
Chronic giardiasis~5–10%Intermittent diarrhoea, steatorrhoea, malabsorption syndrome; lactose intolerance (may persist post-clearance); children: growth stunting, cognitive impairment; persists months to years without treatment
CVID / hypogammaglobulinaemiaNear universal in untreatedChronic severe infection; profound malabsorption; repeated treatment courses required; can be life-threatening from nutritional failure
Post-infectious IBS~10–15% of acute casesPersistent GI symptoms after eradication; altered gut microbiome and epithelial function; lactase deficiency often persists >6 months post-infection

Treatment & Prophylaxis

Tinidazole — First-line (single dose)

2 g orally, single dose; 90–95% cure rate; nitroimidazole class; fewer GI side effects than metronidazole; preferred for compliance simplicity. Avoid in first trimester of pregnancy.

Metronidazole — Effective alternative

250 mg TID × 5–7 days orally; metallic taste and nausea common; alcohol interaction (disulfiram-like); avoid in first trimester. Widely available globally; cure rate ~85–90%.

Nitazoxanide — Broad-spectrum alternative

500 mg BID × 3 days; also active against Cryptosporidium; paediatric liquid formulation (100 mg/5 mL) available; useful for mixed infections and when metronidazole-resistant strains suspected.

Paromomycin — Pregnancy-safe

500 mg TID × 5–10 days; poorly absorbed aminoglycoside; preferred in pregnancy (minimal systemic fetal exposure); efficacy ~60–70%, lower than systemic agents; suitable when other drugs contraindicated.

Prevention

Water filtration or UV treatment (chlorination alone is insufficient — cysts are chlorine-resistant); hand hygiene in childcare and institutional settings; no licensed vaccine available as of 2026.

References

  • Ankarklev J, Jerlström-Hultqvist J, Ringqvist E, Troell K, Svärd SG. Behind the smile: cell biology and disease mechanisms of Giardia species. Nat Rev Microbiol. 2010;8(6):413-22. doi:10.1038/nrmicro2317 · PubMed 20400969
  • Buret AG. Pathophysiology of enteric infections with Giardia duodenalis. Parasite. 2008;15(3):261-5. doi:10.1051/parasite/2008153261 · PubMed 18814694
  • Bennett JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 9th ed. Elsevier; 2020.
  • Murray PR, Rosenthal KS, Pfaller MA. Medical Microbiology. 9th ed. Elsevier; 2021.

Contribute to the Pathogen Atlas

This entry covers Giardia lamblia biology, pathogenesis, and treatment. Post-infectious IBS mechanisms, proteomics of the ventral disc, and VSP regulation are planned expansions. Every entry follows the same schema: structured frontmatter, peer-reviewed citations, and cross-atlas links.